insights_auto
Why is 688235 up ४.०६%?
Dive Deeperchevron_right
688235:SHA
BeOne Medicines AG
CN¥ २५५.९८
arrow_upward
+४.०६%(+९.९९) 1D
अक्टोबर १६, १५:००:०० GMT+८ · CNY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 688235...
Open
CN¥ २५३.२०
High
CN¥ २६८.१८
Low
CN¥ २५२.०९
Mkt. cap
३.०३ खरब
Avg. vol.
२८.०९ लाख
Volume
५६.८८ लाख
P/E ratio
९१.४३
52-wk high
CN¥ ३१९.२४
52-wk low
CN¥ २०५.५१
EPS
CN¥ २.८०
No. of employees
१२ हजार
Open
CN¥ २५३.२०
High
CN¥ २६८.१८
Low
CN¥ २५२.०९
Mkt. cap
३.०३ खरब
Avg. vol.
२८.०९ लाख
Volume
५६.८८ लाख
P/E ratio
९१.४३
52-wk high
CN¥ ३१९.२४
52-wk low
CN¥ २०५.५१
EPS
CN¥ २.८०
No. of employees
१२ हजार
News stories
From web sources and news partners
ad-hoc-news.de
·
१४ घण्टा पहिले
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees१२ हजार
Founded२०१० अक्टोबर २८
Headquarters-
Sector-
Websitebeonemedicines.com